Besides, its pronounced anti-inflammatory effect, anti-IL-23 therapy has shown to improve barrier function in a preclinical psoriasis mouse model where psoriatic lesions were induced using the toll-like receptor 7 agonist imiquimod (21). This evidence concerns the gene IL23A and psoriasis.